<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01261962</url>
  </required_header>
  <id_info>
    <org_study_id>FAPESP:2010/08787-1</org_study_id>
    <nct_id>NCT01261962</nct_id>
  </id_info>
  <brief_title>Modulation of Immune Response by Oral Zinc Supplementation in Chemotherapy for Colon Cancer</brief_title>
  <official_title>Modulation of Immune Response by Oral Zinc Supplementation in Adjuvant Chemotherapy for Colon Cancer: a Study of Global Gene Expression and Function of Humoral Immunity and Neutrophils</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundação de Amparo à Pesquisa do Estado de São Paulo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Sao Paulo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In leukocytes of patients undergoing adjuvant chemotherapy for colon cancer treatment:&#xD;
      a)identify genes modulated by oral supplementation of zinc; b) evaluate the effects of oral&#xD;
      zinc supplementation on humoral immunity and neutrophil function. The study will be conducted&#xD;
      on 30 adult patients aged grater than 18 years, of both genders who have undergone surgical&#xD;
      resection of colonic neoplastic lesions without metastatic lesion. Patients will be&#xD;
      randomized into two groups, with the first (Group QT Zn, n = 15) receive 70 mg/d of zinc for&#xD;
      16 weeks and the second will receive placebo (QT Placebo Group, n = 15). The study will also&#xD;
      include 30 healthy volunteers who receive supplementation of 70 mg/d of Zn (C Zn group, n =&#xD;
      15) or placebo (Group C Placebo, n = 15). Zinc supplementation or placebo for all study&#xD;
      groups will start two days before the volunteers received the pneumococcal vaccine,&#xD;
      polyvalent 23. Fifteen days after vaccination, patients begin chemotherapy as pre-established&#xD;
      criteria by the Oncology Service. Will be monitored the parameters of nutritional status&#xD;
      (anthropometry, bioelectrical impedance, food intake, and laboratory tests) adverse effects,&#xD;
      according to rules of the CTCAE. In the evaluation of humoral immunity, antibodies&#xD;
      opsonization and in the pneumococcal polysaccharide will be measured. Will be evaluated the&#xD;
      function of neutrophils by measuring DNA NETs and quantified calprotectin and elastase&#xD;
      released in the culture supernatants of activated neutrophils. RT-qPCR will be done of genes&#xD;
      differentially expressed(DEGS) on activated leukocytes. In six volunteers from each group&#xD;
      will be analyzed global gene expression from RNA extracted from leukocytes by microarray;&#xD;
      will be detected and correlated the molecular pathways modulated by zinc by MetaCore software&#xD;
      (GeneGo). The DEGS will be validated by RT-qPCR.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>February 2011</start_date>
  <completion_date type="Anticipated">August 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Gene expression</measure>
    <time_frame>18 months</time_frame>
    <description>Modulation of genes related to immune response</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Humoral immunity and neutrophil function</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Adjuvant Chemotherapy</condition>
  <condition>Colon Cancer</condition>
  <condition>Immunity</condition>
  <arm_group>
    <arm_group_label>Chemotherapy and zinc</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in adjuvant chemotherapy supplemented with zinc</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemotherapy placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients in adjuvant chemotherapy with placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control and zinc</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Healthy patients supplemented with zinc</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Healthy volunteers received placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>zinc</intervention_name>
    <description>zinc sulfate, 35 mg twice daily for 4 months</description>
    <arm_group_label>Chemotherapy and zinc</arm_group_label>
    <arm_group_label>Control and zinc</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo, One capsule, twice daily for 4 months</description>
    <arm_group_label>Chemotherapy placebo</arm_group_label>
    <arm_group_label>Control Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age greater than 18 years&#xD;
&#xD;
          -  Diagnostic histopathology of colon cancer stage III (Dukes' stage C)&#xD;
&#xD;
          -  Performance Scale Karnofsky greater or equal to 70%&#xD;
&#xD;
          -  Have been subjected to resection of the primary neoplastic lesion in more than 8 weeks&#xD;
             before start of chemotherapy&#xD;
&#xD;
          -  Patient in the first cycle of chemotherapy in adjuvant XELOX regimen.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with a history of autoimmune or inflammatory disease, active infectious&#xD;
             disease, liver disease, renal failure or diabetes mellitus&#xD;
&#xD;
          -  Patients with metastatic disease&#xD;
&#xD;
          -  Have previously received radiotherapy or chemotherapy&#xD;
&#xD;
          -  Use of GCSF-Granulokine ® (growth-stimulating factor granulocyte)&#xD;
&#xD;
          -  Use of immunosuppressive drugs, diuretics and supplements of zinc or copper.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Selma Freire C. Cunha, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Sao Paulo University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Camila Bitu M. Braga, Msc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sao Paulo University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Camila Bitu M. Braga, Msc</last_name>
    <phone>55-16-36023369</phone>
    <email>camilabitu@usp.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Selma Freire C. Cunha, PhD</last_name>
    <phone>55-16-36013369</phone>
    <email>sfreire@fmrp.usp.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Departament of Clinical Oncology, Sao Paulo University</name>
      <address>
        <city>Ribeirao Preto</city>
        <state>Sao Paulo</state>
        <zip>14049-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <contact>
      <last_name>Camila Bitu M. Braga, Msc</last_name>
      <phone>55-16-36023369</phone>
      <email>camilabitu@usp.br</email>
    </contact>
    <contact_backup>
      <last_name>Selma Freire C. Cunha, PhD</last_name>
      <phone>55-16-36023369</phone>
      <email>sfreire@fmrp.usp.br</email>
    </contact_backup>
    <investigator>
      <last_name>Fernanda Maris Peria, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Camila Bitu M. Braga, Msc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>December 2010</verification_date>
  <study_first_submitted>December 16, 2010</study_first_submitted>
  <study_first_submitted_qc>December 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2010</study_first_posted>
  <last_update_submitted>December 16, 2010</last_update_submitted>
  <last_update_submitted_qc>December 16, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 17, 2010</last_update_posted>
  <responsible_party>
    <name_title>Selma Freire de Carvalho da Cunha</name_title>
    <organization>University of Sao Paulo</organization>
  </responsible_party>
  <keyword>Humoral immunity</keyword>
  <keyword>Neutrophil function</keyword>
  <keyword>Gene expression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

